Plasma Renin Activity (PRA) was determined in a group of 50 Cameroonian newborns and 50 Cameroonian children aged 1-15 years under resting conditions in order to establish baseline values, and also to investigate the relationship between PRA distribution, and blood pressure levels, age, or body weight. Mean PRA values were 0.98 +/- 0.78 ng/ml/h at birth and 1.17 +/- 0.92 ng/ml/h in older children. These values did not correlate with birth weight, age, or blood pressure levels. These results are lower than figures reported in comparable groups of American white and black children, and also in European or Asian children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/tropej/36.3.128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Primary Aldosteronism Masquerading as Bartter and Gitelman Syndromes.
Cureus
December 2024
Department of Medicine, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, IND.
Primary aldosteronism (PA) is a common cause of secondary hypertension, with familial hyperaldosteronism (FH) contributing to a lesser number of cases. FH type IV, a rare subtype, has hardly been reported as a subtype of PA cases. We present a case of a 27-year-old female who presented to the emergency department with circumoral tingling and numbness.
View Article and Find Full Text PDFDirect Vascular Effects of Angiotensin II (A Systematic Short Review).
Int J Mol Sci
December 2024
Department of Physiology, Faculty of Medicine, Semmelweis University, 37-47 Tűzoltó Street, 1094 Budapest, Hungary.
The octapeptide angiotensin II (Ang II) is a circulating hormone as well as a locally formed agonist synthesized by the angiotensin-converting enzyme (ACE) of endothelial cells. It forms a powerful mechanism to control the amount and pressure of body fluids. All main effects are directed to save body salt and water and ensure blood pressure under basic conditions and in emergencies.
View Article and Find Full Text PDFRemission of Insulin-Dependent Diabetes Mellitus in Multiple Endocrine Neoplasia Type 2A After Adrenalectomy.
JCEM Case Rep
January 2025
Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo 162-8666, Japan.
A 37-year-old man presented with symptoms of polyuria and weight loss over the past year. Initial laboratory examination showed elevated blood glucose level (468 mg/dL [25.9 mmol/L]; normal reference range [RR], 75-109 mg/dL [4.
View Article and Find Full Text PDFZilebesiran and Hypertension: A Systematic Review and Meta-analysis.
J Saudi Heart Assoc
December 2024
College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Objectives: Zilebesiran is an investigational RNA interference therapeutic designed to lower blood pressure by targeting the hepatic production of angiotensinogen, the most upstream precursor of the renin-angiotensin-aldosterone system. This approach aims to offer long-lasting blood pressure control with potentially fewer doses compared to traditional antihypertensive medications. The objective of this systematic review and meta-analysis was to assess the antihypertensive efficacy of zilebesiran in patients with hypertension.
View Article and Find Full Text PDFEffect of exercise on kidney-relevant biomarkers in the general population: a systematic review and meta-analysis.
BMJ Open
January 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Objective: Physical activity (PA) has been generally recognised as beneficial for health. The effect of a change in PA on kidney biomarkers in healthy individuals without kidney disease remains unclear. This manuscript synthesised the evidence of the association of changes in PA with kidney biomarkers in the general population free from kidney disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!